Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 4/20 | 0.67 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727626 | 1.00 | MIF (0.67) | MIFNOS3NOS2LMNACYP2C19 | |
| SCHEMBL6970517 | 1.00 | MIF (0.67) | MIFNOS3NOS2LMNACYP2C19 | |
| SCHEMBL9227592 | 0.90 | MIF (0.52) | MIFNOS3NOS2LMNACYP2C19 | |
| SCHEMBL111009 | 0.86 | MIF (0.50) | MIFNOS3NOS2LMNAGABRA1 | |
| SCHEMBL6744506 | 0.85 | MIF (0.49) | MIFNOS3NOS2LMNACYP2C19 | |
| SCHEMBL9467887 | 0.84 | MIF (0.49) | MIFNOS3NOS2LMNACYP2C19 | |
| SCHEMBL4640624 | 0.83 | MIF (0.46) | MIFNOS3NOS2LMNACYP2C19 | |
| SCHEMBL23527635 | 0.82 | MIF (0.46) | MIFNOS3NOS2LMNACYP2C19 | |
| SCHEMBL21259586 | 0.82 | MIF (0.46) | MIFNOS3NOS2LMNACYP2C19 | |
| SCHEMBL330826 | 0.82 | MIF (0.44) | MIFNOS3NOS2LMNAGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108970-A | Diamide derivatives and pharmaceutical application thereof | 四川大学华西医院 | 2022-09-27 | — | — | CN | disclosed |
| CN-107849816-B | Method for treating paperboard and paper media and related treated paperboard and paper media | 巴斯夫欧洲公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-106232667-B | Polyiso-ureas | 巴斯夫欧洲公司 | 2020-01-07 | — | — | CN | disclosed |
| US-20180298557-A1 | METHODS FOR TREATING PAPERBOARDS AND PAPER MEDIA, AND ASSOCIATED TREATED PAPERBOARDS AND PAPER MEDIA | BASF CORPORATION | 2018-10-18 | — | — | US | disclosed |
| EP-3107946-B1 | A POLYISO-UREA | BASF SE (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-9982083-B2 | Polyiso-urea | BASF SE (DE) | 2018-05-29 | — | — | US | disclosed |
| EP-3298194-A2 | METHODS FOR TREATING PAPERBOARDS AND PAPER MEDIA, AND ASSOCIATED PAPERBOARDS AND PAPER MEDIA | BASF SE (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-20170058075-A1 | POLYISO-UREA | BASF SE (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170058074-A1 | POST-MODIFIED POLYCARBODIIMIDES | BASF SE (DE) | 2017-03-02 | — | — | US | disclosed |
| EP-3107946-A1 | A POLYISO-UREA | BASF SE (DE) | 2016-12-28 | — | — | EP | disclosed |
| WO-2010063774-A1 | NOVEL 4-(AZACYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-10 | — | — | WO | disclosed |
| EP-2185542-A2 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2010-05-19 | — | — | EP | disclosed |
| WO-2010010150-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | WO | disclosed |
| US-20090270355-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| WO-2009077741-A2 | 3-SUBSTITUTED-4-OXO-3,4-DIHYDRO-IMIDAZO-[5,1-D][1,2,3,5-TETRAZINE-8-CARBOXYLIC ACID AMIDES AND THEIR USE | PHARMINOX LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009047336-A1 | PHTHALAZINE AND PYRIDO [3,4-D] PYRIDAZ INE COMPOUNDS AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009021965-A2 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017671-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080194549-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194549-A1 | Organic Compounds | REN, ACE, OTC | MIF 3090/4885NOS3 181/4885NOS2 827/4885 |
| US-20090270355-A1 | Compounds | CMA1, HRH4, CCL11 | MIF 1605/4885NOS3 483/4885NOS2 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.